Product Description
PharmAust is developing Monepantel as a treatment for pet dog naive B cell lymphoma. (Sourced from: https://www.pharmaust.com/petdogtrial/)
Mechanisms of Action: nAChR Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | European Medicines Agency | Poland
Approved Indications: None
Known Adverse Events: None
Company: PharmAust
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Amyotrophic Lateral Sclerosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MON-2023-001 | P1 |
Recruiting |
Amyotrophic Lateral Sclerosis |
2025-04-01 |
|
| MON-2021-001 | P1 |
Completed |
Amyotrophic Lateral Sclerosis |
2023-11-29 |
43% |